Strs Ohio Sells 32,917 Shares of Bristol Myers Squibb Company $BMY

Strs Ohio lowered its stake in Bristol Myers Squibb Company (NYSE:BMY) by 6.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 499,705 shares of the biopharmaceutical company’s stock after selling 32,917 shares during the period. Strs Ohio’s holdings in Bristol Myers Squibb were worth $30,307,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Keybank National Association OH increased its position in shares of Bristol Myers Squibb by 3.1% during the 1st quarter. Keybank National Association OH now owns 524,469 shares of the biopharmaceutical company’s stock valued at $31,809,000 after purchasing an additional 15,960 shares during the last quarter. TSG Advice Partners LLC bought a new stake in Bristol Myers Squibb in the first quarter worth $315,000. Root Financial Partners LLC boosted its stake in Bristol Myers Squibb by 144.1% during the first quarter. Root Financial Partners LLC now owns 7,379 shares of the biopharmaceutical company’s stock worth $448,000 after buying an additional 4,356 shares during the period. CHICAGO TRUST Co NA boosted its stake in Bristol Myers Squibb by 9.6% during the first quarter. CHICAGO TRUST Co NA now owns 40,730 shares of the biopharmaceutical company’s stock worth $2,470,000 after buying an additional 3,567 shares during the period. Finally, Fulton Bank N.A. increased its position in Bristol Myers Squibb by 2.9% during the first quarter. Fulton Bank N.A. now owns 8,694 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 241 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BMY shares. HSBC raised their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Bank of America reduced their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Guggenheim reaffirmed a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Trading Down 0.1%

NYSE BMY opened at $58.05 on Friday. The stock has a market cap of $118.54 billion, a PE ratio of 16.31, a PEG ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company’s 50-day moving average price is $56.90 and its 200-day moving average price is $57.49. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.